2,6-diphenyl-pteridin-4-ylamine | 88783-89-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 蝶啶及其衍生物
• 英文名称: 2,6-diphenyl-pteridin-4-ylamine
• 英文别名: 2,6-Diphenylpteridin-4-amine
• CAS: 88783-89-5
• 化学式: C₁₈H₁₃N₅
• 分子量: 299.335
• InChiKey: PBDIBKDFKRLTMZ-UHFFFAOYSA-N

物化性质

• 熔点：
  287-290 °C
• 沸点：
  446.8±45.0 °C(Predicted)
• 密度：
  1.305±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  77.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-异亚硝基苯乙酮 、 2-Phenyl-4,5,6-triaminopyrimidine Hydrochloride 以 甲醇 为溶剂， 反应 2.0h， 以88%的产率得到2,6-diphenyl-pteridin-4-ylamine
  参考文献：
  名称：

  一种合成2,6-二取代的4-氨基蝶啶的通用的区域选择性新方法

  摘要：

  描述了一种制备2，6-二取代的4-氨基蝶啶的新的合成方法。在MeOH中用α-酮醛肟处理2-取代的4,5,6-三氨基嘧啶，可以进行区域选择性的一步反应，高产率地生成2,6-二取代的4-氨基哌啶。

  DOI：

  10.1016/s0040-4039(97)01619-5

文献信息

• A new, general and regioselective method for the synthesis of 2,6-disubstituted 4-aminopteridines
  作者：Shahriyar Taghavi-Moghadam、Wolfgang Pfleiderer

  DOI：10.1016/s0040-4039(97)01619-5

  日期：1997.9

  A new synthetic method for the preparation of 2,6-disubstituted 4-aminopteridines is described. Treatment of 2-substituted 4,5,6-triaminopyrimidines with α-ketoaldoximes in MeOH affords in a regioselective one-step reaction 2,6-disubstituted 4-aminopteridines in high yield.

  描述了一种制备2，6-二取代的4-氨基蝶啶的新的合成方法。在MeOH中用α-酮醛肟处理2-取代的4,5,6-三氨基嘧啶，可以进行区域选择性的一步反应，高产率地生成2,6-二取代的4-氨基哌啶。
• Inhibition of Neuronal Nitric Oxide Synthase by 4-Amino Pteridine Derivatives:  Structure−Activity Relationship of Antagonists of (6<i>R</i>)-5,6,7,8-Tetrahydrobiopterin Cofactor
  作者：Lothar G. Fröhlich、Peter Kotsonis、Hermann Traub、Shahriyar Taghavi-Moghadam、Najim Al-Masoudi、Heinrich Hofmann、Hartmut Strobel、Hans Matter、Wolfgang Pfleiderer、Harald H. H. W. Schmidt

  DOI：10.1021/jm981129a

  日期：1999.10.1

  The family of nitric oxide synthases (NOS) catalyzes the conversion of L-arginine to L-citrulline and nitric oxide (NO), an important cellular messenger molecule which has been implicated in the pathophysiology of septic shock and inflammatory and neurodegenerative disease states. NOS can be maximally activated by the ubiquitous cofactor, (6R)-5,6,7,8-tetrahydrobiopterin (H(4)Bip), and antagonists of H(4)Bip may be of therapeutic importance to inhibit pathologically high NO formation. The 4-amino substituted analogue of H(4)Bip was reported to be a potent NOS inhibit-or. Therefore, we developed a series of novel 4-amino pteridine derivatives, antipterins, to pharmacologically target the neuronal isoform of nitric oxide synthase (NOS-I). To functionally characterize the pterin/anti-pterin interaction and establish a structure-activity relationship (SAR), we systematically altered the substituents in the 2-, 4-, 5-, 6-, and 7-position of the pteridine nucleus. Varying the substitution pattern in the 2-, 5-, and 7-position resulted in no significant inhibitory effect on enzyme activity. In contrast, bulky substituents in the B-position, such as phenyl, markedly increased the inhibitory potency of the reduced 4-amino-5,6,7,8-tetrahydropteridines, possibly as a consequence of hydrophobic interactions within NOS-I. However, this was not the case for the aromatic 4-amino pteridines. Interestingly, chemical modification of the 4-amino substituent by dialkyl/diaralkylation together with 6-arylation of the aromatic 2,4-diamino pteridine resulted in potent and efficacious inhibitors of NOS-I, suggesting possible hydrophilic and hydrophobic interactions within NOS-I. This SAR agrees with (a) the recently published crystal structure of the oxygenase domain of the inducible NOS isoform (NOS-II) and (b) the comparative molecular field analysis of selected NOS-I inhibitors, which resulted in a 3D-QSAR model of the pterin binding site interactions. Further optimization should be possible when the full length structure of NOS-I becomes available.